Via practica 6/2009
Overview of resulsts in selected phramacoeconomic study of betablocker carvedilol
Heart failure patients have very high morbidity and mortality. The clinical application of medicines and delivering of care in this particular group of patients is expanding rapidly. Many of these therapies are life saving, yet each system has only limited healthcare resources. Cost and effectiveness of therapy becomes an important issue in the heart failure population. Carvedilol studies are very good example of short-term and long-term cost-saving management approach to chronic heart failure patients.
Keywords: carvedilol, chronic heart failure, cost-effectiveness
